Pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer
Patients must have histologically confirmed ER+ and/or PR+, HER2-, early invasive breast cancer.
Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically confirmed HER2-negative localized breast cancer by core biopsy.
Participants must have histologically or cytologically confirmed invasive breast cancer
Histologically confirmed invasive cancer of the breast
Subjects with histologically confirmed metastatic or unresectable breast cancer
Histologically confirmed diagnosis of invasive breast cancer
Histologically proven invasive adenocarcinoma of breast
Histologically-confirmed, primary, invasive breast cancer diagnosed within 5 years of study entry
Subjects with histologically confirmed metastatic breast cancer that is either TNBC or HR-positive
Patients with histologically confirmed intact primary cancer that is confirmed invasive carcinoma of the breast, with at least 1.0 cm residual disease as measured by mammography, ultrasound, or breast magnetic resonance imaging (MRI) after neoadjuvant anthracycline based chemotherapy
Subjects have histologically confirmed adenocarcinoma of the breast - all breast cancer subtypes are allowed
Histologically confirmed breast cancer
Newly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT1 or T2, N0-1, and M0
Histologically confirmed diagnosis of invasive breast cancer
Histologically confirmed diagnosis of invasive breast cancer
Newly diagnosed histologically confirmed invasive breast cancer
Histologically confirmed HER2-positive metastatic breast cancer
Histologically confirmed diagnosis of invasive or non-invasive breast cancer
Histologically confirmed invasive primary breast cancer
Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically confirmed invasive breast cancer
Female with histologically confirmed breast cancer
Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
Histologically or cytologically confirmed metastatic breast cancer
Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>) 2 cm
Patients must have histologically confirmed invasive breast cancer with a primary tumor >= 2 cm in greatest dimension as measured by clinical or radiologic examination
Postmenopausal women with histologically or cytologically confirmed invasive, ER+/HER- (defined by local guidelines) metastatic or inoperable, locally advance breast cancer
History of histologically-confirmed bilateral breast cancer
Histologically or cytologically confirmed invasive breast cancer with distant metastasis
PHASE II: Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
Participants must have histologically confirmed HER2+ (3+ by immunohistochemistry and/or FISH ratio >= 2.0) invasive breast cancer; central confirmation of HER2 status is not required
Histologically confirmed invasive cancer of the breast.
Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically confirmed Stage I to III invasive breast cancer. Subjects may have more than one synchronous primary breast tumor.
Patients must have histologically or cytologically confirmed invasive cancer of the breast
Histologically confirmed primary invasive adenocarcinoma of the breast
Pathologically confirmed invasive cancer of the breast
Histologically or cytologically documented breast cancer
Histologically or cytologically confirmed HER2-positive invasive breast cancer, with Stage IV disease;
Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
Patients with histologically confirmed invasive breast cancer, stage I - IV, treated at Lyndon B. Johnson General Hospital in the Harris Health System
Prior history of histologically confirmed bilateral invasive breast cancer
Histologically or cytologically confirmed breast cancer
A history of histologically-confirmed bilateral invasive breast cancer
Histologically confirmed metastatic breast cancer
Diagnosed with histologically-proven invasive breast cancer
Histologically confirmed cT0-4, N1 breast cancer
Group I: Diagnosis of histologically confirmed invasive breast cancer
Group II: Diagnosis of histologically confirmed invasive breast cancer
Women with histologically proven invasive breast cancer and no distant metastases and;
Patients must have histologically confirmed invasive breast cancer
Histologically or cytologically confirmed primary breast cancer.
